Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD
Launched by INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS · Jun 3, 2019
Trial Information
Current as of July 22, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed Aspirin exacerbated respiratory disease.
- • Controled asthma
- • No actual systemic corticosteroid treatment
- • No antileucotriene treatment.
- Exclusion Criteria:
- • Patients who do not complete both phases of the study
- • Patients unable to perform adecuate spyrometric testing
- • Patients who present severe asthmatic reactions with high salycilate foods
About Instituto Nacional De Enfermedades Respiratorias
The Instituto Nacional de Enfermedades Respiratorias (INER) is a leading research institution dedicated to the study and treatment of respiratory diseases in Mexico. As a pivotal clinical trial sponsor, INER focuses on advancing knowledge and improving therapeutic strategies for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary infections. With a commitment to high standards of scientific rigor and ethical conduct, INER collaborates with healthcare professionals, academic institutions, and industry partners to facilitate innovative research and enhance patient care in the field of respiratory health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mexico City, Ciudad De Mexico, Mexico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials